Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Thanh Chung Vu"'
Autor:
Sara Corvigno, Yuan Liu, Emine Bayraktar, Elaine Stur, Nazende Nur Bayram, Adrian Lankenau Ahumada, Supriya Nagaraju, Cristian Rodriguez-Aguayo, Hu Chen, Thanh Chung Vu, Yunfei Wen, Han Liang, Li Zhao, Sanghoon Lee, Gabriel Lopez-Berestein, Anil K. Sood
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Small RNAs (microRNAs [miRNAs] or small interfering RNAs [siRNAs]) are effective tools for cancer therapy, but many of the existing carriers for their delivery are limited by low bioavailability, insufficient loading, impaired transport acro
Externí odkaz:
https://doaj.org/article/087c961034464f26a8c8679bea773cfa
Autor:
Robiya Joseph, Santosh K. Dasari, Sujanitha Umamaheswaran, Lingegowda S. Mangala, Emine Bayraktar, Cristian Rodriguez-Aguayo, Yutuan Wu, Nghi Nguyen, Reid T. Powell, Mary Sobieski, Yuan Liu, Mark Seungwook Kim, Sara Corvigno, Katherine Foster, Pahul Hanjra, Thanh Chung Vu, Mamur A. Chowdhury, Paola Amero, Clifford Stephan, Gabriel Lopez-Berestein, Shannon N. Westin, Anil K. Sood
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 2, p 1278 (2024)
Endometrial cancer is the most frequent malignant tumor of the female reproductive tract but lacks effective therapy. EphA2, a receptor tyrosine kinase, is overexpressed by various cancers including endometrial cancer and is associated with poor clin
Externí odkaz:
https://doaj.org/article/11cd5500e55d4c058edd52dd9cc1a32e
Autor:
Thi Bich Uyen Le, Thanh Chung Vu, Rebecca Zhi Wen Ho, Aldo Prawira, Lingzhi Wang, Boon Cher Goh, Hung Huynh
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 24, p 9405 (2020)
The fibroblast growth factor (FGF) signaling cascade is one of the key signaling pathways in hepatocellular carcinoma (HCC). FGF has been shown to augment vascular endothelial growth factor (VEGF)-mediated HCC development and angiogenesis, as well as
Externí odkaz:
https://doaj.org/article/b497f51e34854350aea5f5019526d3af
Autor:
Yuan Liu, Adrian Lankenau Ahumada, Emine Bayraktar, Paul Schwartz, Mamur Chowdhury, Sixiang Shi, Manu M. Sebastian, Htet Khant, Natalia de Val, Nazende Nur Bayram, Guodong Zhang, Thanh Chung Vu, Zuliang Jie, Nicholas B. Jennings, Cristian Rodriguez-Aguayo, Jody Swain, Elaine Stur, Lingegowda S. Mangala, Yutuan Wu, Supriya Nagaraju, Brooke Ermias, Chun Li, Gabriel Lopez-Berestein, Janet Braam, Anil K. Sood
Publikováno v:
Journal of Controlled Release. 357:472-483
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a8e2b2b122da5197462cc855b0056ea
https://doi.org/10.1016/j.jconrel.2023.03.056
https://doi.org/10.1016/j.jconrel.2023.03.056
Publikováno v:
Liver International
Background & Aims Infigratinib is a pan‐FGFR (fibroblast growth factor receptor) inhibitor that has shown encouraging activity in FGFR‐dependent hepatocellular carcinoma (HCC) models. However, long‐term treatment results in the emergence of res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78a5418cef16031d17b44bac1a221337
https://doi.org/10.1111/liv.14728
https://doi.org/10.1111/liv.14728
Autor:
Thanh Chung Vu, Alan Huang, Thi Bich Uyen Le, Hung Huynh, Youzhen Wang, Huaixiang Hao, Aldo Prawira, Diana Graus Porta
Publikováno v:
Experimental & Molecular Medicine
Hepatocellular carcinoma (HCC) is a lethal cancer with limited therapeutic options, and standard therapy with sorafenib provides only modest survival benefits. Fibroblast growth factor 19 (FGF19) has been proposed as a driver oncogene, and targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c662a4b400fa64cd3d0c8016a2c52dac
https://doi.org/10.1038/s12276-020-00524-4
https://doi.org/10.1038/s12276-020-00524-4
Autor:
Septian Hartano, Philip Lee, Choon Hua Thng, Tong San Koh, Rebecca Zhi Wen Ho, Aldo Prawira, Way Cherng Chen, Hung Huynh, Xing Qi Teo, Anh Tran, Thanh Chung Vu, Thi Bich Uyen Le
Publikováno v:
Molecular imaging and biology. 23(1)
Overexpression of fibroblast growth factor receptor (FGFR) contributes to tumorigenesis, metastasis, and poor prognosis of hepatocellular carcinoma (HCC). Infigratinib—a pan-FGFR inhibitor—potently suppresses the growth of high-FGFR-expressing HC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48dc496d9796cd608fae555b68adf6d4
https://pubmed.ncbi.nlm.nih.gov/32909245
https://pubmed.ncbi.nlm.nih.gov/32909245
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Rebecca Zhi Wen Ho, Boon Cher Goh, Thanh Chung Vu, Hung Huynh, Aldo Prawira, Thi Bich Uyen Le, Lingzhi Wang
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 24
International Journal of Molecular Sciences, Vol 21, Iss 9405, p 9405 (2020)
Volume 21
Issue 24
International Journal of Molecular Sciences, Vol 21, Iss 9405, p 9405 (2020)
The fibroblast growth factor (FGF) signaling cascade is one of the key signaling pathways in hepatocellular carcinoma (HCC). FGF has been shown to augment vascular endothelial growth factor (VEGF)-mediated HCC development and angiogenesis, as well as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89a5b78e13f94838ea236a2c6613ae37
https://doi.org/10.3390/ijms21249405
https://doi.org/10.3390/ijms21249405